UAE – TVM Capital Healthcare, through its TVM Healthcare Afiyah Fund, has invested €10 million (approximately US$11 million) into Amsterdam-headquartered medical devices company DEBx Medical.

This news comes shortly after TVM Capital Healthcare Partners inaugurated a new office in Riyadh in the Kingdom of Saudi Arabia.

Regulated by the Dubai Financial Services Authority, TVM Capital Healthcare is exploring growth capital and buyout investments in fast-growing companies in emerging market economies.

It has developed its global presence through investments in the United States, Europe, and South East Asia while recruiting local healthcare advisory and operating expertise to its international team.

The private equity firm is exploring investment opportunities in the Emerging Markets of the Middle East and North Africa (MENA), India, Turkey, and selected geographies in South East Asia.

TVM Capital Healthcare’s investment in DEBx Medical will enable the company to commence commercialization of its ground-breaking product, DEBRICHEM.

DEBRICHEM is intended for topical application to an infected non-healing wound, to eliminate infection by removing biofilm and by this infection, then followed by cleaning and dressing

On his part, Tristan de Boysson, Managing Partner of TVM Capital Healthcare, said: “With this investment, we will accelerate the market introduction of a product that will transform the management of chronic wounds, and improve the lives of millions of patients.”

The objective of this investment is to support DEBx Medical’s efforts of deploying its single-use medical device to eliminate wound infections across the Middle Eastern and African markets.

These funds will be utilized to ensure patients can access innovative products for the management of chronic wounds, and ultimately, improve the lives of millions of patients worldwide.

DEBx Medical will use part of the funding to construct and establish a regional headquarter and a production base in the Middle East and North Africa region.

This investment is also part of our Fund’s strategy of bringing innovative, best-in-class healthcare solutions to the wider MENA region. We are looking forward to working together with the DEBx Medical management team,” underscored Tristan de Boysson.

With the latest capital injection, DEBx Medical will deploy its promising innovative wound care solution into the MENA region as the company expands its global footprint and builds its presence in the region.

The Dutch company is expected to fast-track access to its DEBRICHEM product, which offers a superior alternative to existing treatments for non-healing chronic wounds.

Moreover, DEBx Medical has received regulatory clearance to begin commercial production of its CE-marked and IS0-certified DEBRICHEM, a novel desiccant agent used for chemical debridement.

This innovative product is easy to use and highly effective in removing biofilm and curing hard-to-heal wounds, which impacts the patient’s quality of life and represents a substantial cost to healthcare systems.

For this reason, DEBx Medical will help to tackle healthcare challenges in the treatment of chronic wounds in the Gulf Cooperation Council (GCC) countries.

These strategic moves will build on the company’s mission to be a key player in the chronic wound care market and help patients to heal fast, safely, and effectively.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.